Stockscreener 앱 받기
1.15
1.71%
-0.02
시간 외 거래:
1.15
전일 마감가:
$1.17
열려 있는:
$1.17
하루 거래량:
115.35K
Relative Volume:
0.45
시가총액:
$11.60M
수익:
$200.00K
순이익/손실:
$-11.46M
주가수익비율:
-0.3144
EPS:
-3.6582
순현금흐름:
$-9.76M
1주 성능:
+0.00%
1개월 성능:
+10.58%
6개월 성능:
-59.79%
1년 성능:
-49.33%
1일 변동 폭
$1.12
$1.185
1주일 범위
$1.09
$1.185
52주 변동 폭
$1.02
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
명칭
Soligenix Inc
전화
609-538-8200
주소
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.15 | 11.80M | 200.00K | -11.46M | -9.76M | -3.6582 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-28 | 다운그레이드 | Dawson James | Buy → Neutral |
| 2018-01-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 재확인 | Maxim Group | Buy |
| 2017-07-17 | 개시 | H.C. Wainwright | Buy |
Soligenix Inc 주식(SNGX)의 최신 뉴스
Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach - The Globe and Mail
SNGX Earnings History & Surprises | EPS & Revenue Results | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
SNGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behcet Disease - Digital Journal
Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit - Digital Journal
Soligenix (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology - Digital Journal
SNGX Should I Buy - Intellectia AI
Soligenix receives positive EMA opinion for orphan drug status - Investing.com Australia
Biopharmaceutical company Soligenix, Inc. recently announced that its application for orphan drug designation for SGX945, developed for the treatment of Behçet's Disease, has received a positive opinion from the European Medicines Agency (EMA). - Bitget
Soligenix receives positive EMA opinion for orphan drug status By Investing.com - Investing.com UK
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease - Barchart.com
SNGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Growth Value: Is Soligenix Inc a speculative investmentOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Soligenix to Present at BIO Investment Summit - Intellectia AI
Soligenix to Present at BIO Investment & Growth Summit - ChartMill
Soligenix CEO to Present at BIO Investment Summit Amid Key Clinical Developments - citybuzz -
SNGX PE Ratio & Valuation, Is SNGX Overvalued - Intellectia AI
Will Soligenix Inc. face regulatory challenges2025 Stock Rankings & Proven Capital Preservation Methods - mfd.ru
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Armistice Capital and Steven Boyd report 4.99% stake in Soligenix (SNGX) - Stock Titan
Why Soligenix Inc. stock is favored by top institutions2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru
Soligenix, Inc. Announces Adjournment of Annual Meeting, Informa - GuruFocus
Will Soligenix Inc. stock split attract more investors2025 Geopolitical Influence & AI Forecasted Stock Moves - mfd.ru
Analysts Offer Insights on Healthcare Companies: Soligenix (SNGX) and Boston Scientific (BSX) - The Globe and Mail
Soligenix Provides Shareholder Update on Rare Disease Pipeline - TipRanks
Will Soligenix Inc. (DOA0) stock beat international competitionJuly 2025 Intraday Action & Stepwise Trade Execution Plans - mfd.ru
Soligenix (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options - Digital Journal
Soligenix Details Recent Progress and Upcoming Milestones - Morningstar
Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - Digital Journal
Soligenix’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - The Globe and Mail
Exit Recap: Is Soligenix Inc a speculative investment2025 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
Short Interest in Soligenix Inc. (NASDAQ:SNGX) Decreases By 12.5% - Defense World
Soligenix (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer - The Globe and Mail
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape - The Globe and Mail
Soligenix (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM) - Digital Journal
Soligenix Advances Novel Visible Light Therapy for Challenging Cutaneous T-cell Lymphoma - citybuzz -
Soligenix's HyBryte Therapy Shows Promise for Early-Stage Cutaneous T-Cell Lymphoma Treatment - citybuzz -
Soligenix Advances Novel Visible Light Therapy for Early-Stage Cutaneous T-Cell Lymphoma - MEXC
RiVax(R) Positions Soligenix (NASDAQ: SNGX) in Growing Biodefense Preparedness Efforts - Digital Journal
Soligenix Establishes At-The-Market Equity Offering Program - The Globe and Mail
Soligenix’s RiVax Vaccine Advances as Ricin Threats Highlight Biodefense Needs - citybuzz -
Soligenix enters sales agreement with Rodman - marketscreener.com
Soligenix Inc Enters Sales Agreement With Rodman - TradingView
Soligenix Enters At Market Issuance Sales Agreement - TradingView
Soligenix (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease - Digital Journal
Soligenix’s SGX945 in Behcet’s disease published in Rheumatology (Oxford) - MSN
Soligenix Reports Positive Phase 2 Results for Behçet’s Disease Treatment - citybuzz -
Soligenix (NASDAQ: SNGX) Advances Solutions for Hard-to-Diagnose CTCL - The Globe and Mail
Soligenix Inc (SNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):